Comparative Pharmacology
Head-to-head clinical analysis: KENGREAL versus PLAVIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENGREAL versus PLAVIX.
KENGREAL vs PLAVIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cangrelor is a reversible, direct-acting P2Y12 platelet receptor antagonist that inhibits ADP-mediated platelet activation and aggregation.
Clopidogrel is a prodrug that is converted to an active metabolite by CYP450 enzymes. The active metabolite selectively inhibits the P2Y12 component of ADP receptors on the platelet surface, which prevents ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
10 mcg/kg intravenous bolus over 1-2 minutes, followed by 0.1 mcg/kg/min continuous intravenous infusion for 2-4 hours.
75 mg orally once daily, with or without food. For acute coronary syndrome, a loading dose of 300 mg (or 600 mg for PCI) is given followed by 75 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3–6 minutes (mean 3.3 minutes), allowing rapid recovery of platelet function within 60 minutes of infusion cessation.
Clopidogrel parent: ~6 hours; active thiol metabolite: ~30 minutes; terminal half-life of inactive metabolite(s): ~8 hours. Clinically, platelet inhibition persists for 5–7 days due to irreversible P2Y12 receptor binding.
Cangrelor is metabolized via rapid dephosphorylation to its major metabolite, a nucleoside, which is further degraded; approximately 58% of the dose is excreted in urine as unchanged cangrelor and metabolites, with <35% in feces.
Renal: ~50% as inactive metabolites; biliary/fecal: ~50% as inactive metabolites.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent